Navigation Links
Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Date:8/28/2007

- On track to have Phase 3 data available by the spring of 2009 - - Filing of global marketing authorization applications expected by the

fall of 2009 -

ROCKVILLE, Md., Aug. 28 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has completed enrollment and initial dosing ahead of schedule in ACHIEVE 1, the first of two pivotal Phase 3 trials of Albuferon(R) (albinterferon alfa-2b) in combination with ribavirin in treatment-naive patients with chronic hepatitis C. Albuferon is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO )

"We have completed enrollment in the ACHIEVE 1 trial ahead of schedule and now expect to have Phase 3 data available for Albuferon by the spring of 2009, with global marketing applications anticipated in the fall of 2009," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "Assuming success in Phase 3 trials, we believe that Albuferon could become the interferon of choice in treatment regimens for hepatitis C."

HGS previously projected enrollment of both Phase 3 trials by the end of 2007. A total of 1331 patients at 150 clinical sites in 12 countries have been enrolled and randomized in ACHIEVE 1, which is being conducted in treatment-naive patients with genotype 1 chronic hepatitis C. ACHIEVE 2/3 was initiated in February 2007, and will enroll and randomize a minimum of 918 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C. Enrollmen
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Apollos human proteins boost stem cell research
5. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
6. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
7. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
8. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
9. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
10. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
11. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... N.J. and LOS ANGELES ... Diagnostics (NYSE: DGX ), the world,s leading ... it has completed the previously announced acquisition of ... As a result of the transaction, ... extensive range of innovative services and network of ...
(Date:8/4/2015)... 2015  Sutro Biopharma today announced that it ... vice president of alliance and project management. Dr. ... management of Sutro,s collaborative partnerships and the development ... bispecific antibodies and antibody-based therapeutics targeting immuno-oncology pathways. ... years of experience in the biopharmaceutical sector with ...
(Date:8/4/2015)... 4, 2015  Delcath Systems, Inc. (NASDAQ: DCTH ... on oncology with an emphasis on the treatment of ... summarizing data from studies in Europe ... Hepatic CHEMOSAT ® Delivery System (CHEMOSAT) will be presented ... congress, which will be held in Marseille, ...
Breaking Medicine Technology:Quest Diagnostics Completes Acquisition of MemorialCare Health System's Laboratory Outreach Service Business in Southern California 2Sutro Biopharma Appoints Nicki Vasquez, Ph.D. as VP of Alliance and Project Management 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 3Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 4
... Inc., a neurology-focused specialty pharmaceutical company, announced today that ... of CAMBIA™ (diclofenac potassium for oral solution) will be ... Neurology Conference (CONy) in Barcelona, Spain. The ... entitled, "Rapid and Sustained Improvement in Migraine Symptoms with ...
... joint guideline by the American Society of Hematology (ASH) ... physicians about the appropriate use of erythropoiesis-stimulating agents (ESAs), ... to produce more red blood cells, to treat cancer ... ESAs are associated with shorter survival and increased risk ...
Cached Medicine Technology:New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology 2New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology 3New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology 4New Guideline from ASH and ASCO Recommends Caution Regarding ESA Use in Cancer Patients 2New Guideline from ASH and ASCO Recommends Caution Regarding ESA Use in Cancer Patients 3
(Date:8/4/2015)... (PRWEB) , ... August 05, 2015 , ... The ... Pain and Obesity ”. , As corresponding author Professor Akiko Okifuji says “Both obesity ... often, although it is not to say that one causes the other. Rather, there ...
(Date:8/4/2015)... ... 2015 , ... Exsurco Medical, Inc. is proud ... as an Affiliate Member. Exsurco Medical finds this an exciting opportunity to ... lives by promoting the safety, quality and availability of donated tissue for transplantation, ...
(Date:8/4/2015)... ... 2015 , ... The United Nations Foundation today announced a ... for a select group of U.S.-based journalists during the week of November 9, ... International Conference on Family Planning in Bali. , In close coordination with ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... formula. Healthy Origins® Cognizin® is a trademark for Citicoline, a nutrient that ... a capsule for those applications which have more of a semi-solid composition. ...
(Date:8/4/2015)... ... 2015 , ... Bayco Products, Inc. announces a new industrial-grade LED Dual-LightTM headlamp ... hats that have a flip-up face shield. The sleek contours of the new ... to remove their headlamp when raising or lowering their face shield or visor. The ...
Breaking Medicine News(10 mins):Health News:The Association between Chronic Pain and Obesity published by Dove Medical Press 2Health News:Exsurco Medical Joins AATB as Affiliate Member 2Health News:UN Foundation Announces Press Fellowship to Indonesia with Focus on Women’s Health and Rights 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 3Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3
... in Wonderland was well advised to stay asleep especially as ... in the tea-time conversation. Dormice in Europe spend about eight ... extended period, with almost all of them surviving the winter. ... Austria, the Czech Republic, England, Germany and Italy. Karin Lebl ...
... close attention to how the United Kingdom carries out plans ... beyond clinical and cost effectiveness, according to researchers at the ... to appear in the April 7 issue of the ... discuss a new, "value-based pricing" policy proposed by the British ...
... -- Having a good laugh on April Fool,s Day or ... benefits your blood vessels, an expert says. "Laughter increases ... stress is especially beneficial for persons who have hypertension [high ... Vascular Surgery news release. April is National Stress Awareness ...
... a unique system to perform in vivo RNAi ... that regulate hepatocyte proliferation during chronic liver damage.1 ... stable knockdown of the candidate gene by different ... mouse hepatocytes and also increase the regenerative capacity ...
... 1 issue of the journal SLEEP demonstrates that an ... sleep disturbances, as well as providing positive, indirect benefits ... that the Internet can give parents widespread access to ... children. Results show that there were significant improvements ...
... Researchers have found that it may not be necessary to ... analyzing non-tumor tissue may be an effective option, according to ... of the American Association for Cancer Research. "A ... detect the presence of tumor," said lead researcher Dan Mercola, ...
Cached Medicine News:Health News:Sleeping through danger: the dormouse approach to survival 2Health News:Placing value, price on new drugs: The challenge facing new UK policy, say Hopkins bioethicists 2Health News:Placing value, price on new drugs: The challenge facing new UK policy, say Hopkins bioethicists 3Health News:Internet program reduces infant and toddler sleep problems, helps moms sleep better too 2Health News:Internet program reduces infant and toddler sleep problems, helps moms sleep better too 3Health News:New tool allows for an alternate method of prostate cancer diagnosis 2
For the quantitative in vitro determination of creatinine in serum, plasma or urine....
For the quantitative in vitro determination of Magnesium in serum, plasma and urine...
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum...
For the quantitative in vitro determination of IgE in Human Serum or Plasma....
Medicine Products: